Novartis to Take Earnings Hit From Generic Competition -- Market Talk

Dow Jones03-30

0936 GMT - Novartis's first-quarter earnings are set to drop on year, as generic competition and its acquisition of Avidity hit margins, Bank of America analysts say in a research note. Bank of America expects the Swiss pharmaceutical company to report first-quarter core EPS of $2.07, down 10% on year at constant currency and short of consensus estimates of $2.13. The analysts say their forecast for Novartis's quarterly sales of $13.3 billion is in line with consensus estimates, but they anticipate worse generic pressure and the recently closed Avidity deal to dilute margins. Novartis seems likely to reiterate its full-year guidance and continue to signal an inflection point for growth in the second half, the analysts add. Shares rise 0.5%. (adria.calatayud@wsj.com)

(END) Dow Jones Newswires

March 30, 2026 05:37 ET (09:37 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment